Hikma Pharmaceuticals PLC
HKMPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $3 | $3 | $3 | $3 |
| % Growth | 8.8% | 14.2% | -1.4% | – |
| Cost of Goods Sold | $2 | $1 | $1 | $1 |
| Gross Profit | $1 | $1 | $1 | $1 |
| % Margin | 45.3% | 48.9% | 50.3% | 51% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $1 | $1 | $1 | $0 |
| SG&A Expenses | $1 | $1 | $1 | $0 |
| Sales & Mktg Exp. | $0 | -$0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $1 | $1 | $1 |
| Operating Income | $1 | $0 | $0 | $1 |
| % Margin | 19.6% | 12.8% | 11.2% | 22.8% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | $0 | $0 | $0 | $1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 11.5% | 6.6% | 7.5% | 16.5% |
| EPS | 1.62 | 0.85 | 0.84 | 1.82 |
| % Growth | 90.6% | 1.2% | -53.8% | – |
| EPS Diluted | 1.61 | 0.85 | 0.84 | 1.81 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $1 | $1 | $1 | $1 |
| % Margin | 25.2% | 27.5% | 27.5% | 27.6% |